We performed 1-year follow-up of 2022 high-risk patients with NSTE-ACS undergoing urgent PCI , who were randomized to abciximab or placebo after pre-treatment with 600 mg clopidogrel in the Intracoronary Stenting and Antithrombotic Regimen : Rapid Early Action for Coronary Treatment 2 trial .
